626 related articles for article (PubMed ID: 16275990)
1. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
[TBL] [Abstract][Full Text] [Related]
3. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
[TBL] [Abstract][Full Text] [Related]
4. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents.
Mercatante DR; Mohler JL; Kole R
J Biol Chem; 2002 Dec; 277(51):49374-82. PubMed ID: 12381725
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
Miayake H; Tolcher A; Gleave ME
J Natl Cancer Inst; 2000 Jan; 92(1):34-41. PubMed ID: 10620631
[TBL] [Abstract][Full Text] [Related]
6. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
Lebedeva I; Rando R; Ojwang J; Cossum P; Stein CA
Cancer Res; 2000 Nov; 60(21):6052-60. PubMed ID: 11085527
[TBL] [Abstract][Full Text] [Related]
7. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
Milella M; Trisciuoglio D; Bruno T; Ciuffreda L; Mottolese M; Cianciulli A; Cognetti F; Zangemeister-Wittke U; Del Bufalo D; Zupi G
Clin Cancer Res; 2004 Nov; 10(22):7747-56. PubMed ID: 15570009
[TBL] [Abstract][Full Text] [Related]
9. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death.
Jiang Z; Zheng X; Rich KM
J Neurochem; 2003 Jan; 84(2):273-81. PubMed ID: 12558990
[TBL] [Abstract][Full Text] [Related]
11. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
12. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.
Castilla C; Congregado B; Chinchón D; Torrubia FJ; Japón MA; Sáez C
Endocrinology; 2006 Oct; 147(10):4960-7. PubMed ID: 16794010
[TBL] [Abstract][Full Text] [Related]
13. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy.
Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N
Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
Hopkins-Donaldson S; Cathomas R; Simões-Wüst AP; Kurtz S; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
Int J Cancer; 2003 Aug; 106(2):160-6. PubMed ID: 12800189
[TBL] [Abstract][Full Text] [Related]
15. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
[TBL] [Abstract][Full Text] [Related]
16. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
[TBL] [Abstract][Full Text] [Related]
18. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
19. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
Smythe WR; Mohuiddin I; Ozveran M; Cao XX
J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1191-8. PubMed ID: 12063468
[TBL] [Abstract][Full Text] [Related]
20. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
